Supernus Pharmaceuticals Inc

SUPN

Add to Watchlist

49.430USD

-1.770-3.46%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Supernus Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

44 / 155

Overall Ranking

121 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative-

Supernus Pharmaceuticals Inc Highlights

StrengthsRisks

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 18.34% year-on-year.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -96.74, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 66.06M shares, increasing 0.36% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 778.00 shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

62.833

Target Price

+22.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Supernus Pharmaceuticals Inc is 7.42, ranking 107 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 207.71M, representing a year-over-year increase of 38.63%, while its net profit experienced a year-over-year increase of 80.61%.

Score

Industry at a Glance

Previous score

7.42

Change

0



Financials

6.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

3.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.90

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.59

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Supernus Pharmaceuticals Inc is 6.05, ranking 133 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -96.74, which is -1606.65% below the recent high of 1457.52 and -63.10% above the recent low of -157.78.

Score

Industry at a Glance

Previous score

6.05

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 44/155

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Supernus Pharmaceuticals Inc is 8.33, ranking 42 out of 155 in the Pharmaceuticals industry. The average price target is 61.50, with a high of 65.00 and a low of 50.00.

Score

Industry at a Glance

Previous score

8.33

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Supernus Pharmaceuticals Inc is 7.30, ranking 43 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 52.64 and the support level at 46.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.10

Change

-1.8

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Supernus Pharmaceuticals Inc is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 113.82%, representing a quarter-over-quarter increase of 9.85%. The largest institutional shareholder is Steven Cohen, holding a total of 2.26M shares, representing 3.90% of shares outstanding, with 585.08% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

7.82M

+2.33%

Millennium Management LLC

3.28M

+8.09%

Armistice Capital LLC

2.76M

-2.54%

Nomura Investment Management Business Trust

2.31M

-8.84%

Dimensional Fund Advisors, L.P.

2.71M

-9.65%

Point72 Asset Management, L.P.

Star Investors

2.26M

+28.57%

State Street Investment Management (US)

2.22M

+1.45%

Khattar (Jack A)

2.25M

+1.56%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Supernus Pharmaceuticals Inc is 6.07, ranking 60 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.58. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Supernus Pharmaceuticals Inc

SUPN

7.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

9.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment